Korea Drug Development Fund CEO Joo Sang-aun (left) and Mathai Mammen, senior vice president of cardiovascular diseases, metabolic diseases, immunology and oncology at U.S.-based pharmaceutical company Merck Sharp & Dohme signed a memorandum of understanding Tuesday at the 2016 BIO International Convention taking place in San Francisco. The two have agreed to launch a new joint research and development program geared at linking Korea’s new drug development capabilities with global pharmaceutical companies, the KDDF said. (KDDF)
MOST POPULAR